Imbruvica Boosts CLL Lead With First-Line Claim
AbbVie Inc. and Johnson & Johnson's BTK inhibitor Imbruvica (ibrutinib) has reinforced its lead position in the chronic lymphocytic leukemia market with a first-line indication from FDA.
AbbVie Inc. and Johnson & Johnson's BTK inhibitor Imbruvica (ibrutinib) has reinforced its lead position in the chronic lymphocytic leukemia market with a first-line indication from FDA.